Open AccessP1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN‐LABEL, 2‐ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON‐HODGKIN LYMPHOMA (INHL)
Author(s) -
Vorobyev V.,
Yoon D. H.,
Kaźmierczak M.,
Grosicki S.,
Tarella C.,
Genua A.,
Kim J. S.,
Cohan D.,
Daugherty M.,
Flinn I. W.,
Zinzani P. L.,
Gordon L. I.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847360.49139.75
Subject(s) - medicine , dosing , tolerability , clinical endpoint , adverse effect , nausea , phases of clinical research , bristol myers , clinical trial